pk 11195 has been researched along with Central Nervous System Disease in 2 studies
PK-11195 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 1-(2-chlorophenyl)isoquinoline-3-carboxylic acid with the amino group of sec-butylmethylamine
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Scarf, AM | 1 |
Ittner, LM | 1 |
Kassiou, M | 1 |
Visigalli, I | 1 |
Moresco, RM | 1 |
Belloli, S | 1 |
Politi, LS | 1 |
Gritti, A | 1 |
Ungaro, D | 1 |
Matarrese, M | 1 |
Turolla, E | 1 |
Falini, A | 1 |
Scotti, G | 1 |
Naldini, L | 1 |
Fazio, F | 1 |
Biffi, A | 1 |
1 review available for pk 11195 and Central Nervous System Disease
Article | Year |
---|---|
The translocator protein (18 kDa): central nervous system disease and drug design.
Topics: Acetamides; Apoptosis; Central Nervous System; Central Nervous System Diseases; Drug Design; Humans; | 2009 |
1 other study available for pk 11195 and Central Nervous System Disease
Article | Year |
---|---|
Monitoring disease evolution and treatment response in lysosomal disorders by the peripheral benzodiazepine receptor ligand PK11195.
Topics: Animals; Brain; Carbon Radioisotopes; Central Nervous System Diseases; Demyelinating Diseases; Disea | 2009 |